Galicia's cost-cutting drug catalogue challenged by Spanish government in court
This article was originally published in Scrip
Spain's central government is to appeal against an autonomous regional authority that has introduced its own reimbursement list for medicines, which differs from the centrally approved list. The pharmaceutical industry is likely to pay close attention to the case, which could affect whether other regional authorities break rank with central pricing and reimbursement policies to create an increasingly uncertain market.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.